Mathai Mammen - Jan 3, 2022 Form 3 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Pharm, R&D
Signature
Raavi Deol, as attorney-in-fact for Mathai Mammen
Stock symbol
JNJ
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
3
Date filed
1/13/2022, 03:43 PM
Previous filing
Jun 15, 2021
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding JNJ Common Stock 32.5K Jan 3, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JNJ Employee Stock Options (Right to Buy) Jan 3, 2022 Common Stock 28.9K $129.51 Direct F1
holding JNJ Employee Stock Options (Right to Buy) Jan 3, 2022 Common Stock 36.1K $131.94 Direct F1
holding JNJ Employee Stock Options (Right to Buy) Jan 3, 2022 Common Stock 58.1K $151.41 Direct F1
holding JNJ Employee Stock Options (Right to Buy) Jan 3, 2022 Common Stock 43.1K $164.62 Direct F1
holding JNJ Restricted Share Units Jan 3, 2022 Common Stock 36K Direct F2
holding JNJ Restricted Share Units Jan 3, 2022 Common Stock 3.93K Direct F2
holding JNJ Restricted Share Units Jan 3, 2022 Common Stock 4.55K Direct F2
holding JNJ Restricted Share Units Jan 3, 2022 Common Stock 7.42K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vested and exercisable on the third anniversary of the date of the grant.
F2 Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.

Remarks:

mammenpoa1.txt